Zambian 2013 Budget Reviewed by Kampamba Shula

On 12 October 2012, the Minister of Finance, Hon. Alexander Bwalya Chikwanda, MP, announced the 2013 National Budget. Budget highlights and taxation and other changes as contained in the Budget speech and the Zambia Revenue Authority (“ZRA”) publication.

INDECO (IDC): Past Problems and Opportunities Analysed by Kampamba Shula

INDECO (IDC): Past Problems and Opportunities Analysed

Critical Review of IMF 2013 Zambia ARTICLE IV CONSULTATION report by Kampamba Shula

Debt management is still on track The agreed norm is that for internal borrowing the threshold is 25 per cent of GDP but our debt stands at K17 billion, which is 15 per cent of GDP and for external borrowing, the threshold is 40 per cent and our debt is US$3.1 billion which is 14 per cent of GDP, so we are far below the agreed norms. So even in the long term , Zambia is still on track.

US Economy 2014 First Quarter Analysis and Outlook by Kampamba Shula

New data shows the U.S. economy contracted in the first quarter of this year, keeping pace with shifting expectations but down sharply from the prior already disappointing estimate.

Zambia Debt Analysis

Some might say that Zambia should not borrow externally and even as sincere as they may be they are wrong. When the Government borrows locally “Crowing out” happens.

Wednesday, February 20, 2013

The Euro Analysed by Kampamba Shula



The Euro

Introduction

The euro is the single currency shared by (currently) 17 of the European Union's Member States, which together make up the euro area. The introduction of the euro in 1999 was a major step in European integration: around 330 million EU citizens now use it as their currency.

When the euro was launched on 1 January 1999, it became the new official currency of 11 Member States, replacing the old national currencies – such as the Deutschmark and the French franc – in two stages. First the euro was introduced as an accounting currency for cash-less payments and accounting purposes, while the old currencies continued to be used for cash payments. Since 1 January 2002 the euro has been circulating in physical form, as banknotes and coins. The euro is not the currency of all EU Member States. Two countries (Denmark and the United Kingdom) have ‘opt-out’ clauses in the Treaty exempting them from participation, while the remainders (several of the more recently acceded EU members plus Sweden) have yet to meet the conditions for adopting the single currency (European Commission, 2011).
 

All EU Member States form part of Economic and Monetary Union (EMU), which can be described as an advanced stage of economic integration based on a single market. It involves close co-ordination of economic and fiscal policies and, for those countries fulfilling certain conditions, a single monetary policy and a single currency – the euro. The process of economic and monetary integration in the EU parallels the history of the Union itself. When the EU was founded in 1957, the Member States concentrated on building a 'common market'. However, over time it became clear that closer economic and monetary co-operation was desirable for the internal market to develop and flourish further. But the goal of achieving the EMU including a single currency was not enshrined until the 1992 Maastricht Treaty (Treaty on European Union), which set out the ground rules for its introduction. These state what the objectives of EMU are, who is responsible for what, and what conditions Member States must meet in order to adopt the euro. These conditions are known as the 'convergence criteria' (or 'Maastricht criteria') and include low and stable inflation, exchange rate stability and sound public finances (European Commission, 2011).

With the launch of the euro monetary policy became the responsibility of the independent European Central Bank (ECB), which was created for that purpose, and the national central banks of the Member States having adopted the euro. Together they compose the Eurosystem. Fiscal policy (public revenue and expenditure) remains in the hands of individual national authorities – although they undertake to adhere to commonly agreed rules on public finances known as the Stability and Growth Pact. Member States also retain overall responsibility for their structural policies (i.e. labour markets, pension and capital markets), but agree to co-ordinate them in order to achieve the common economic goals (European Commission, 2011).

Apart from making travelling easier within the EU, a single currency makes economic and political sense. The framework under which the euro is managed underpins its stability, contributes to low inflation and encourages sound public finances. A single currency is also a logical complement to the single market and contributes to making it more efficient. Using a common currency increases price transparency, eliminates currency exchange costs, facilitates international trade and gives the EU a more powerful voice in the world. The size and strength of the euro area also better protect it from external economic shocks, such as unexpected oil price rises or turbulence in the currency markets. Last but not least, the euro gives the EU’s citizens a tangible symbol of their European identity.

 

Against the background of the current debt crisis important measures to improve the economic governance in the EU and the euro area in particular have been taken. EU Member States have strengthened the Stability and Growth Pact, introduced a new mechanism to prevent or correct macroeconomic imbalances and are increasingly coordinating structural policies. These are crucial steps to strengthen the "E" - the economic leg - of the EMU and to ensure the success of the euro in the long run (European Commission, 2011).

 

Economeka Analysis the Current state , Structure, the Flaws and the Inevitable

Current State

To break the ice I must indicate that I have full faith that the Euro will not break up. A look at the price insurance against wild swings in the currency will confirm my assertions.

According to a Bloomberg report the options market is signaling the threat of a breakup in the 17-nation euro bloc is disappearing as the price of insurance against wild swings in the region’s single currency fall to a five-year low (Masaki Kondo, 2013).

Butterfly options that protect against both gains and declines slid to the lowest since March 2008 on Feb. 4. Implied volatility on three-month options on the euro-dollar exchange rates has risen about half as much as a broader gauge of currency volatility this year. The currencies of nations with top credit ratings have dropped against the euro over the past six months as concern eased that Europe’s currency union would unravel. The bonds of Greece, Portugal, Ireland, Spain and Italy -- the region’s most indebted-economies-- have been the best performers among sovereign debt in that period, indexes tracked by Bloomberg and the European Federation of Financial Analyst Societies show (Masaki Kondo, 2013).

Stress in European funding markets has eased since July, according to the Bloomberg Financial Conditions Monitor, the same month European Central Bank President Mario Draghi pledged to do whatever it takes to preserve the monetary union (Masaki Kondo, 2013).

The shared currency has appreciated 4 percent over the past three months and 7.1 percent over the past six, according to Bloomberg Correlation-Weighted Indexes, which track 10 developed-nation currencies. It has climbed more than 10 percent on a trade-weighted basis since Draghi’s pledge in July.

 

Draghi spurred gains in the euro last month when he spoke of “positive contagion” in financial markets and a return to economic growth later this year. The ECB cut its benchmark rate to a record low of 0.75 percent in July.

 

“Concerns of a break-up of the single currency and general global economic concerns have eased,” Alan Wilde, head of fixed-income and currencies in London at Baring Asset Management, which oversees $53 billion, said in a telephone interview on Feb. 14. “Some of these tail risks have dissipated as actions have been taken and markets have gained more confidence.” (Masaki Kondo, 2013)

The Flaws

The flaws of the Euro stem mainly from the lack of fiscal and structural consolidation. Public revenue and expenditure still remain in the hands of individual countries. Structural policies on labor, pensions and capital markets also remain the hands of individual countries. While such autonomy has been necessary at a domestic level it has generally gone against the best interest of the Euro region as a whole.

If the Euro is to succeed and which I have no doubt in my mind that it will, there will be need for greater fiscal and structural consolidation. Now when I say this I don’t mean it the way most economists would say it, rather more boldly I mean fiscal and structural policy decision making authority at a broader level will have to be given to the European Central Bank. “The European Central Bank must become a fully-fledged central bank,” Former Italian Prime Minister Silvio Berlusconi said. “That means it should guarantee the sovereign debt of all countries that use the euro as a currency.”

There will be many who would oppose such an assertion but it is the only way to streamline policy across the Euro region. To some nations it will mean surrendering a portion of their sovereignty of which I will admit will have to be the case.

The current status quo makes it ineffective for the much needed structural reforms to take place. Talks of austerity are not received very well by the masses of peripheral nations in debt. A closer look at Greece which has suffered from years of poor fiscal and structural management will show the issues at hand. For example Greece's structural problems go back a long way. We are talking about chronic deficits, declining competitiveness and poor public sector performance. Foreign investment has been static for a decade. The tax code is opaque and regulations for business are notoriously complex. The country has been on the EU's naughty step for a long time, certainly since 2004 when Athens sensationally announced its previous government "misreported" expenditures. It "discovered" Greece had exceeded the 3% deficit threshold for the Eurozone.

 

The Inevitable

In my personal opinion I consider it inevitable that fiscal and structural consolidation will take place even if it means at a slow pace, it will happen eventually. Given the ECB’s evident support to keep the Euro together it is a safe bet that the Euro will stay together.

The derivation from such an assertion requires fiscal and structural consolidation. 2 things are probable,1 is inevitable. Break up of Euro & 1 Government for the Euro Region. The latter is inevitable.

Bibliography


European Commission. (2011, February 20). Economic and Financial Affairs - The Euro. Retrieved February 20, 2013, from European Commision: http://ec.europa.eu/economy_finance/euro/index_en.htm

Masaki Kondo, L. C. (2013, February 19). Euro Breakup Risk Falls to 5-Year Low in Butterfly: Currencies. Retrieved February 20, 2013, from Bloomberg: http://www.bloomberg.com/news/2013-02-19/euro-breakup-risk-falls-to-5-year-low-in-butterfly-currencies.html

 

 

Wednesday, February 13, 2013

Zambian Kwacha Exchange rate Analysed by Kampamba Shula

Rising food and import costs prompted the Bank of Zambia to raise interest rates and increase the reserve ratios for commercial banks in the past four months, undermining economic growth
Zambia’s central bank plans to sell more dollars to bolster the second worst-performing currency in Africa and curb inflation, officials said. The kwacha, which has slumped 9.6 percent against the dollar in the past six months, needs to be at a “more realistic” level, Governor Michael Gondwe. The Bank of Zambia has already reduced foreign-currency reserves by $36 million this year to support the local unit.

Rising food and import costs prompted the Bank of Zambia to raise interest rates and increase the reserve ratios for commercial banks in the past four months, undermining economic growth. “The exchange rate needs to be right, because if it gets out of hand it has an impact on inflation,” Gondwe said. President Michael Sata has “legitimate concerns” because of the weaker currency and rising costs in the economy. The kwacha’s slide is the worst after Malawi’s currency in the past six months. Finance Minister Alexander Chikwanda said the weaker currency may lead to an inflation spiral and boost the government’s debt costs. The kwacha should trade at 5 to 5.10 a dollar to hold back inflation, he said.

‘Small Advantage’

The depreciation has “a small advantage to the exporters but a huge disadvantage to the economy as we import and service external commitments,” Chikwanda told reporters in Solwezi, near the border with Democratic Republic of Congo. Inflation in Zambia slowed for the first time in six months in January to 7 percent as the government sold stocks of corn, the staple food, to millers at a lower price that it was bought.

Dollar Shortage

The kwacha’s slide is mainly due to a lack of liquidity in the foreign-currency market. Zambia’s current-account deficit of $211 million last year, compared with surpluses in the previous three years, has contributed to the weaker kwacha.

According to Stanley Tamele, head of global markets at Standard Chartered Plc’s Zambian unit the shortage of foreign-currency may be due to mining companies, which account for about 75 percent of Zambia’s export earnings, withholding dollars. (Bloomberg)

Economeka Analysis

The kwacha had been steadily losing ground against the dollar (See Graph above) during the Month of January. This may have been due to Mining companies withholding Dollars possibly for reason that they were not sure how the Kwacha would trade with the Dollar after the rebasing had begun. They may have possibly been waiting to see some clarity in the exchange rate which was not positive as the kwacha kept losing ground against the Dollar during the month of January (see Graph).

As can be seen from the graph the kwacha reached a high of 5.4 which caught the attention of the policy makers who were not ready to see it go higher. Some sort of Dollar injection into the market may have triggered its decline in the recent days(See Graph).

The consequences of a Weak Kwacha come in two forms positive and negative. The problem is the negatives outweigh the positives. The positive is that exporters have an advantage compared to other global competitors as their products will be cheaper on the global market. The negatives are that imports of fuel and manufactured goods become more expensive for Zambia.

Declining export prices (lower copper demand led to lower prices) contrasted with rising import prices and manufactured goods, lead to a worsening of terms of trade. Zambia recorded its first account deficit in 3 years last year.

Given that the Honorable minister would like the Kwacha trading at 5 to 5.1 to prevent Inflation. It would be prudent to align estimations going forward around that range.

Economeka’s estimations remain at 5.1 to 5.3 after central Bank intervention and possibly 5 to 5.2 after Mining companies are comfortable with stability of the Kwacha.

Tuesday, February 12, 2013

Pfizer Stock Analysis Complied by Kampamba Shula


New York-based Pfizer, Inc. is the world’s largest pharmaceutical company in terms of sales. The company has several blockbuster drugs and clearly distanced itself from the rest of its peer group in terms of financial power. In October 2009, Pfizer acquired Wyeth for about 68 billion. Wyeth has some valuable assets, including therapeutic categories complementary to Pfizer, a biologics portfolio, and a vaccine business. In February 2011, Pfizer acquired King Pharmaceuticals for $3.6 billion. With this acquisition, Pfizer is looking to strengthen its pain management franchise. The company’s website is www.pfizer.com

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
Since Ian Read became CEO over a year ago, there has been an intense focus on taking actions that will create shareholder value through increasing productivity of the innovative core and ensuring proper capital allocation that aligns with shareholder interests. The result has been a flurry of activity both in terms of product launches and approvals. Pfizer has taken steps to maximize the value of its inline portfolio, including key assets like Lyrica, Enbrel, Prevnar and Celebrex and advanced the regulatory filing for Eliquis, tofacitinib and the next wave of compounds in the pipeline.
Lipitor

Lipitor (atorvastatin) belongs to a group of drugs called HMG CoA reductase inhibitors, or "statins." Lipitor reduces levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL).
Lipitor is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors.
Pfizer owned the patent for Lipitor which expired in November 2011 and became generic. Lipitor is the bestselling pharmaceutical drug of all time.

Wall Street Analysis

Wall Street analysts look extremely bullish on Pfizer Inc. Their consensus for 2013 implies a forward P/E multiple of 11, down from the 19 figure that arises from comparing the stock’s valuation to trailing earnings. Pfizer is also an attractive defensive stock: its beta is 0.7, meaning that despite its large size it tends to fluctuate less than the broader market does in response to economic conditions, and it pays a dividend yield of 3.4%.
Pfizer can be compared to Merck & Co., Inc. (NYSE:MRK), Novartis AG (NYSE:NVS), Sanofi SA (NYSE:SNY), and Bristol Myers Squibb Co. (NYSE:BMY). Merck and Novartis have similar spreads between their trailing and forward P/Es; respectively, they trade at 21 and 18 times trailing earnings and 11 and 12 times their expected earnings for 2013. All three of those companies- including Pfizer- have similar valuation multiples. Merck and Novartis have slightly higher dividend yields, with Novartis’s being the highest at 4%, though that it is not a particularly big gap either.
Pfizer’s biggest strength is the company’s balance sheet. Pfizer has managed to beef up its already strong balance sheet over the past few quarters. The company has increased its cash position from $17 billion dollars to$23.2 billion dollars in cash. Free cash flow came in at just over $10 billion dollars for the in 2010. Margins are below the industry average at 17% and 9%. Return on equity is low at 8.2%.
Pfizer has become an attractive stock to income investors because of it steady stable revenue stream and solid dividend yield. Pfizer is a good dividend play with its 80 cent payout and 4.4% yield. The current payout rate is 37% of earnings and the stock’s yield is slightly lower than its 4.6% historical yield. The company should be able to steadily grow its dividend over the next few years as earnings slowly increase and the dividend payout ratio increases.

These are the major issues to consider when assessing this stock, according to analysts:

Key Positive Arguments
Key Negative Arguments
  • The company has several blockbuster products in its portfolio.
  • Pfizer lacks a drug that would add to its top-line now that Lipitor has lost exclusivity.
  • The acquisition of Wyeth and agreement with GlaxoSmithKline for HIV treatment development will provide Pfizer with long-term benefits.
  • Many of the key drugs that heightened Pfizer’s stature are experiencing stiff direct competition. Pfizer is a major financial and pharmaceutical company, but its ability to withstand threats to its core franchise remains uncertain.
  • The company’s decision to cut its R&D spend and streamline pipeline activities is being viewed as a major positive by the firms in the Digest group.
  • Pfizer’s pipeline needs to deliver. Major high-profile development setbacks include torcetrapib for high cholesterol, tanezumab for pain (phase III), dalbavancin (Zeven), an antibiotic for the treatment of skin infections, inhaled insulin drug Exubera, Sutent (liver cancer) and melanoma candidate tremelimumab.


Economeka & Ratios

Pfizer offers a decent combination of a reasonable valuation and income for investors. Again, sales growth will be lacking for the foreseeable future, but Pfizer is still very profitable and has ample cushion to adjust its cost structure to maintain a respectable level of profit gains going forward.

Price Earnings Ratios

 

Current P/E Ratio
14.0
P/E Ratio 1 Month Ago
13.7
P/E Ratio 26 Weeks Ago
17.6
P/E Ratio 52 Weeks Ago
16.6
5-Year High P/E Ratio
20.2
5-Year Avg. High P/E Ratio
17.2
5-Year Low P/E Ratio
9.4
5-Year Avg. Low P/E Ratio
11.7
5-Year Avg. P/E Ratio
15.3
Current P/E as % of 5-Year Avg. P/E
91%
P/E as % of 2 Digit MG Group P/E
62%
P/E as % of 3 Digit MG Group P/E
80%
12 Month Normalized P/E Ratio
18.4

 With a price to book value of 2.5, Pfizer is not unreasonably overvalued by the market which shows its valuation is still within reasonable limits. With a Price to Equity ratio of about 13 which is below 20 the general consensus limit for robust growth prospects.

Latest 12 Months Data Items

 
Latest Full Context Quarter Ending Date
2012/09
Gross Profit Margin
84.4%
EBIT Margin
22.5%
EBITDA Margin
42.4%
Pre-Tax Profit Margin
20.1%
Interest Coverage
9.4
Current Ratio
2.0
Quick Ratio
1.5
Leverage Ratio
2.2
Receivables Turnover
2.6
Inventory Turnover
1.2
Asset Turnover
0.3
Revenue to Assets
0.3
ROE from Total Operations
11.9%
Return on Invested Capital
8.6%
Return on Assets
5.3%

 

The Gross Profit margin alone will indicate something is tremendously good about Pfizer. At 84% gross profit and return on invested capital at 8.6% the robust balance sheet of Pfizer is a site for sore eyes for any investor.

The ratios also indicate that Pfizer manages its working capital efficiently as well as its long term and short term debt.

Pfizer remains a strong Buy for 2013 and beyond according to analysis from Economeka.